Has Manish Patel, MD received payments from drug or device companies?

Yes. Drug and device makers reported $29,719,339 in general payments to Manish Patel, MD across 8,460 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Manish Patel, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Manish Patel, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Manish Patel, MD

Medical Oncology · Sarasota, FLNPI 1457408254

Payments from drug & device makers

$29,719,339in general payments, 2019–2025

Across 8,460 payments — averaging $3512.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Daiichi Sankyo Inc.$3.8M
Janssen Research & Development, LLC$3.2M
Eli Lilly$3.1M
Merck$2.7M
Boehringer Ingelheim International GmbH$2.6M
Genentech, Inc.$1.8M
plus $12.4M from 54 others

$15,866in research payments, 2019–2025

Across 9 payments — averaging $1762.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$8K
Boehringer Ingelheim$6K
F. Hoffmann-la Roche AG$2K
TG Therapeutics, Inc.$16

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Daiichi Sankyo Inc.	2,888	$3,837,842
Janssen Research & Development, LLC	440	$3,198,300
Eli Lilly	45	$3,123,793
Merck	1,209	$2,730,218
Boehringer Ingelheim International GmbH	559	$2,576,587
Genentech, Inc.	382	$1,828,167
AstraZeneca(2 entities)	142	$1,321,299
Incyte Corporation	556	$1,159,590
Astrazeneca UK Limited	21	$1,154,937
Boehringer Ingelheim	90	$1,077,087
Bristol Myers Squibb	65	$973,273
Clovis Oncology, Inc.	63	$956,755
Novartis	82	$713,356
Modernatx, Inc.	126	$679,985
E.r. Squibb & Sons, L.L.C.	103	$613,579
Sanofi US Services Inc.	69	$537,377
Blueprint Medicines Corporation	164	$495,804
GSK	102	$455,666
Macrogenics, Inc.	129	$454,367
Tesaro, Inc.	43	$438,949
EMD Serono, Inc.	48	$255,365
Portola Pharmaceuticals, LLC	29	$229,999
Pfizer	81	$222,234
Beigene, Ltd.	83	$140,024
Verastem, Inc.	48	$112,404
AbbVie	61	$108,734
Gilead(2 entities)	69	$103,807
Boehringer Ingelheim Pharma GmbH & Co.kg	102	$59,422
Hoffmann-la Roche Limited	11	$52,906
Sanofi Pasteur Inc.	58	$31,920
Takeda Pharmaceuticals U.S.A., Inc.	12	$14,226
Jazz Pharmaceuticals Inc.	26	$10,953
Intrinsiq Specialty Solutions, Inc.	2	$8,438
Amgen	26	$7,950
Janssen Global Services, LLC	1	$6,500
F. Hoffmann-la Roche AG	3	$4,049
Syndax Pharmaceuticals, Inc.	4	$3,951
Tanabe Pharma America, Inc.	4	$2,940
Johnson & Johnson(3 entities)	82	$2,472
Ipsen Biopharmaceuticals, Inc	4	$2,206
Adaptive Biotechnologies Corporation	9	$2,096
Bayer	18	$1,767
Lilly USA, LLC	51	$1,079
Biontech SE	13	$709
Array Biopharma Inc	28	$577
Seagen Inc.	34	$527
Sanofi	30	$519
Eisai Inc.	20	$431
Astellas Pharma US Inc	19	$343
Genentech USA, Inc.	25	$290
Puma Biotechnology, Inc.	17	$277
Regeneron Healthcare Solutions, Inc.	9	$240
Beigene USA, Inc.	10	$207
Rigel Pharmaceuticals, Inc.	7	$204
Sobi, Inc	10	$186
Beone Medicines USA, Inc.	7	$153
Pharmacyclics LLC, An Abbvie Company	7	$146
Stemline Therapeutics Inc.	5	$131
Geron Corporation	5	$116
Epizyme, Inc.	6	$116

How this compares

$29,719,339 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida →

Medicare billing

Part B allowed, 2024

$239,553

Medicare patients

166

Services billed

16,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Sarasota

Judy WangSarasota$9.8M
Fadi KayaliSarasota$5.9M
Scott LuninSarasota$3M
Anjan PatelSarasota$3M
Zeynep ErogluTampa$30.9M
Jad ChahoudTampa$21.8M
Maen HusseinTavares$18.4M
Patrick HwuTampa$18M
Gail WrightHudson$13.8M
Adil DaudTampa$13.3M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →